Lack of pharmacokinetic interaction between pantoprazole and diclofenac

International Journal of Clinical Pharmacology and Therapeutics

Volumn 34, Issue 4, 1996, Pages 152-156

  Bliesath, H ^a,c   Huber, R ^a   Steinijans, V W ^a   Koch, H J ^a   Wurst, W ^a   Mascher, H ^b  

^a ALTANA PHARMA AG   (Germany)

^b Pharmanalyt GmbH   (Austria)

^c Clinical Pharmacology Department   (Germany)

Author keywords

Diclofenac; Interaction; NSAID; Pantoprazole; Proton pump inhibitor

Indexed keywords

CYTOCHROME P450; DICLOFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; PANTOPRAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; LIVER METABOLISM; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RHEUMATIC DISEASE; STOMACH ACID SECRETION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; BENZIMIDAZOLES; BIOLOGICAL AVAILABILITY; BLOOD PRESSURE; DICLOFENAC; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; OMEPRAZOLE; RANDOM ALLOCATION; SULFOXIDES;

EID: 0029924366     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. +-ATPase inhibitor of pantoprazole after single intravenous administration. Int J Clin Pharmacol Ther 32: 44-50
2. Bliesath H, Huber R, Steinijans VW, Koch HJ, Kunz K, Wurst W 1996 Pantoprazole does not interact with nifedipine in man under steadystate conditions. Int J Clin Pharmacol Ther 34: 51-55
3. De Mey C, Meineke I, Steinijans VW, Huber R, Hartmann M, Bliesath H, Wurst W 1994 Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction. Int J Clin Pharmacol Ther 32: 98-106
4. Diletti E, Hauschke D, Steinijans VW 1991 Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol 29: 1-8
5. Duursema L, Müller FO, Schall R, Middle MV, Hundt HKL, Gr Groenewoud G, Steinijans VW, Bliesath H 1995 Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. Br J Clin Pharmacol 39: 700-703
6. Ehrlich A, Fuder H, Hartmann M, Timmer W, Huber R, Birkel M, Bliesath H, Steinijans VW, Wurst W 1995 Lack of pharmacokinetic and pharmacodynamic interaction of pantoprazole and phenprocoumon in man. Gastroenterology 108 (Suppl): A86
7. Forth W, Henschler D, Rummel W 1987 Allgemeine und spezielle Pharmakologie und Toxikologie. Wissenschaftsverlag, Mannheim
8. Gugler R, Hartmann M, Rudi J, Bliesath H, Brod I, Klotz U, Huber R, Steinijans VW, Wurst W 1992 Lack of interaction of pantoprazole and diazepam in men. AGA meeting 1992, San Francisco, USA. Gastroenterology 102 (Suppl): A77
9. Gugler R, Jensen JC 1985 Omeprazole inhibits oxidative drug metabolism - studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 89: 1235-1241
10. 2-receptor antagonists as clinically important inhibitors of drug metabolism in vivo. Pharmacol Ther 33: 133-137
11. +-ATPase inhibitor pantoprazole (BY1023/SK&F96022) compared to other antiulcer drugs. Meth Find Exp Clin Pharmacol 13: 63-67
12. Hartmann M, Bliesath H, Zech K, Koch H, Steinijans VW, Wurst W, Mascher H 1995a Pantoprazole does not influence CYPIA2 activity in man. Gastroenterology 108 (Suppl): A109
13. Hartmann M, Huber R, Bliesath H, Steinijans VW, Koch HJ, Wurst W 1995b Lack of interaction between pantoprazole and digoxin at therapeutic doses in man. Int J Clin Pharmacol Ther 33: 481-485
14. +-ATPase inhibitor (BY 1023/SK&F96022) and its sulphone metabolite in serum or plasma by direct injection and fully automated pre-column sample clean up. J Chromatogr 529: 389-401
15. Huber R, Hartmann M, Bliesath H, Steinijans VW, Zech K 1996a Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther in press
16. Huber R, Bliesath H, Hartmann M, Koch HJ, Steinijans VW, Mascher H, Wurst W 1996b Pantoprazole does not influence the pharmacokinetics of carbamazepine. Gastroenterology, in press
17. John A 1979 The pharmacokinetics and metabolism of diclofenac sodium (Voltarol) in animals and man. Rheumatol Rehabil 2 (Suppl): 22-37
18. Judmaier G, Koelz HR and Pantoprazol-Duodenal Ulcer-study Group 1994 Comparison of pantoprazole and ranitidine in the treatment of acute duodenal ulcer. Aliment Pharmacol Ther 8: 81-86
19. Koch HJ, Hartmann M, Bliesath H, Huber R, Steinijans VW, Mascher H, Wurst W 1996 Pantoprazole does not influence metoprolol pharmacokinetics and pharmacodynamics in man. Gastroenterology, in press
20. Kromer W, Postius S, Riedel R, Simon WA, Hanauer G. Brand U, Gönne S, Parsons ME 1990 BY1023/SK&f96022, INN pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P450 interactions. J Pharmacol Exp Ther 29: 369-375
21. Leemann T, Transon C, Dayer P 1993 Cytochrome P450TB (CYP2C): A major monooxygenase catalysing diclofenac 4′-hydroxylation in human liver. Life Sci 52: 24-29
22. Mascher H 1989 The pharmacokinetics of a new sustained-release form of diclofenac sodium in humans. Drug Des Deliv 4: 303-311
23. Middle MV, Müller FO, Schall R, Groenewoud G, Hundt HKL, Huber R, Bliesath H, Steinijans VW 1995a No influence of pantoprazole on the pharmacokinetics of phenytoin. Int J Clin Pharmacol Ther 33: 304-307
24. Middle MV, Müller FO, Schall R, Hundt HKL, Mogilnicka EM, Beneke PC 1995b Effect of pantoprazole on ovulation suppression by a low-dose hormonal contraceptive. Clin Drug Invest 9: 54-56
25. Müller P, Simon B, Khalil H, Lühmann R, Leucht U, Schneide r A 1992 Dose range finding study with the proton pump inhibitor pantoprazole in acute duodenal ulcer patients. Z Gastroenterol 30: 771-775
26. Naidu MUR, Shobha JC, Dixit VK, Kumar A, Kumar TR, Sekhar KR, Sekhar EC 1994 Effect of multiple dose omeprazole on the pharmacokinetics of carbamazepine. Drug Invest 7: 8-12
27. Prichard PJ, Walt RP, Kilchingman GK, Somerville KW, Longman MJS, Williams J, Richens A 1987 Oral phenytoin pharmacokinetics during omeprazole therapy. Br J Clin Pharmacol 24: 543-545
28. Sauter R, Steinijans VW, Diletti E, Böhm A, Schulz H-U 1992 Presentation of results from bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 30: 233-256
29. Schepp W, Rehner M, Witzel L 1994 A review of treatment of duodenal and gastric ulcers-pantoprazole vs. omeprazole. Aliment Pharmacol Ther 8 (Suppl 1): 53-57
30. Schulz HU, Hartmann M, Steinijans VW, Huber R, Lührmann B, Bliesath H, Wurst W 1991 Lack of influence of pantoprazole on the disposition kinetics of theophylline in man. Int J Clin Pharmacol Ther Toxicol 29; 369-375
31. Shin JM, Besancon M, Prinz C, Simon A, Sachs G 1994 Continuing development of acid pump inhibitors: site of action of pantoprazole. Aliment Pharmacol Ther 8 (Suppl 1): 11-23
32. +-ATPase inhibitor BY1023/SK&F96022 - inhibition of pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man. Aliment Pharmacol Ther 4: 239-245
33. +-ATPase inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers. Z Gastroenterol 28: 443-447
34. Somerville K, Faulkner G, Longman M 1986 Non-steroidal antiinflammatory drugs and bleeding peptic ulcer. Lancet I: 489-492
35. Steinijans VW, Hartmann M, Huber R. Radtke HW 1991 Lack of pharmacokinetic interaction as equivalence problem. Int J Clin Pharmacol Ther Toxicol 29: 323-328
36. Sutfin T, Balmer K, Bostrom H, Erikson S, Hoglund P, Paulsen O 1989 Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 11: 176-184
37. Todd PA, Sorkin EM 1988 Diclofenac sodium reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 35: 244-285
38. Willis JV, Kendall MJ, Jack DB 1981 The influence of food on the absorption of diclofenac after single and multiple oral dose. Eur J Clin Pharmacol 19: 33-37
39. Witzel L, Gütz H, Hüttemann W, Schepp W 1995 Pantoprazole versus omeprazole in the treatment of acute gastric ulcers. Aliment Pharmacol Ther 9: 19-24